Abstract:Introduction: Alzheimer's disease (AD) is an intensifying neurodegenerative illness due to its irreversible nature. Identification of β-site Amyloid Precursor Protein (APP) cleaving en-zyme1 (BACE1) has been a significant medicinal focus towards AD treatment, and this has opened ground for several investigations. Despite the numerous works in this direction, no BACE1 inhibitor has made it to the final approval stage as an anti-AD drug. Methods: We provide an introductory background of the subject with a general overview of the pathogenesis of AD. The review features BACE1 inhibitor design and development with a focus on some clinical trials and discontinued drugs. Using the topical keywords BACE1, inhibitor design, and computational/theoretical study in the Web of Science and Scopus database, we retrieved over 49 relevant articles. The search years are from 2010 and 2020, with analysis conducted from May 2020 to March 2021. Results and discussion: Researchers have employed computational methodologies to unravel po-tential BACE1 inhibitors with a significant outcome. The most used computer-aided approach in BACE1 inhibitor design and binding/interaction studies are pharmacophore development, quantita-tive structure-activity relationship (QSAR), virtual screening, docking, and molecular dynamics (MD) simulations. These methods, plus more advanced ones including quantum mechan-ics/molecular mechanics (QM/MM) and QM, have proven substantial in the computational frame-work for BACE1 inhibitor design. Computational chemists have embraced the incorporation of in vitro assay to provide insight into the inhibition performance of identified molecules with potential inhibition towards BACE1. Significant IC50 values up to 50 nM, better than clinical trial com-pounds, are available in the literature. Conclusion: The continuous failure of potent BACE1 inhibitors at clinical trials is attracting many queries prompting researchers to investigate newer concepts necessary for effective inhibitor de-sign. The considered properties for efficient BACE1 inhibitor design seem enormous and require thorough scrutiny. Lately, researchers noticed that besides appreciable binding affinity and Blood-Brain Barrier (BBB) permeation, BACE1 inhibitor must show low or no affinity for permeability-glycoprotein. Computational modeling methods have profound applications in drug discovery strat-egies. With the volume of recent in silico studies on BACE1 inhibition, the prospect of identifying potent molecules that would reach the approved level is feasible. Investigators should try pushing many of the identified BACE1 compounds with significant anti-AD properties to preclinical and clinical trial stages. We also advise computational research on allosteric inhibitor design, exosite modeling, and multisite inhibition of BACE1. These alternatives might be a solution to BACE1 drug discovery in AD therapy.

It's good to know what to BACE the specificity of your inhibitors on

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

BACE1 Inhibitors for Alzheimer's Disease: Current Challenges and Future Perspectives

Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

Molecular Mechanism of Binding Selectivity of Inhibitors Toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions.

The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment

BACE Inhibitor Clinical Trials for Alzheimer's Disease

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

BACE1 controls synaptic function through modulating release of synaptic vesicles

BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease

Distinct Transcriptional Regulation and Function of the Human Bace2 and Bace1 Genes

Control of App Processing and A Beta Generation Level by Bace1 Enzymatic Activity and Transcription

Determining Structural Changes for Ligand Recognition between Human and Rat Phosphorylated BACE1 in Silico and Its Phosphorylation by GSK3β at Thr252 by in Vitro Studies

Unmasking BACE1 in aging and age-related diseases

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species